ANTIMICROBAL AND ANTIFUNGAL PROPHYLAXIS IN PATIENTS WITHMULTIPLE MYELOMA, THAT RECEIVE CYCLOPHOSPHAMIDE FORMOBILIZATION OF HEMATOPOIETIC STEM CELLS
Abstract
BACKGROUND Bacterial and fungal infections are the most common complication in patients withhematological diseases treated with chemotherapy. Autologous hematopoietic stem cell transplantation is the most effective treatment of patients with multiple myeloma. Mobilizationof hematopoietic stem cells (HSC), which allows collection of stem cells from peripheral venous blood, is induced by cyclophosphamide and granulocyte-colony stimulating factor(g-CSF). Cyclophosphamide is a toxic alkylating cytostatic agent that can cause severe neutropenia. METHODS The purpose of this randomized retrospective study was to find out the efficacy of antimicrobal and antifungal prophylaxis with ciprofloxacine and fluconazole, respectively, inpatients with multiple myeloma, that received cyclophosphamide (4g/m2) for mobilizationof HSC. RESULTS Altogether 112 myeloma patients that underwent autologous haematopoietic stem cell transplantation between years 2001–2007 were included in the study. In the expected intervalof neutropenia (from fifth day on after aplication of cyclophosphamide), 69 (62 %)patients received ciprofloxacin, 34 (30 %) patients also received fluconazole and 43(55 %) patients did not have any antimicrobal or antifungal prophylaxis. Leukopenia wasfound in 43 (55 %) patients on the tenth day after administration of cyclophosphamide.Patients, who did not have any preventive treatment had approximately three timeshigher incidence of systemic infections. Etiology of infections was determined in onlyseven out of 23 patients. In one patient we suspected a respiratory tract infection withAspergilus fumigatus. CONCLUSIONS Prophylaxis with ciprofloxacin in multiple myeloma patients, who receive cyclophosphamide for mobilization of haematopoetic blood cells, is warranted. On the contrary, prophylaxis with fluconazole does not seem to be necessaryDownloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
